Research Progress of Anti-cancer Strategies Based on ERK1/2 Post-translational Modification and Spatial Regulation
10.3971/j.issn.1000-8578.2024.23.1332
- VernacularTitle:基于ERK1/2翻译后修饰调控及空间性调节的抗癌策略研究进展
- Author:
Ting GUO
1
;
Mengyu SHANG
2
;
Yin GUO
3
;
Weiren HUANG
4
,
5
Author Information
1. Graduate School, Guangxi University of Chinese Medicine, Nanning 530200, China.
2. School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518061, China.
3. Department of Pharmacology, School of Medicine, Shantou University, Shantou 515041, China.
4. Graduate School, Guangxi University of Chinese Medicine, Nanning 530200, China
5. Instibute of Translational Medicine, The Second People’s Hospital of Shenzhen, Shenzhen 518025, China.
- Publication Type:REVIEWS
- Keywords:
ERK1/2;
Tumor;
Targeted therapy;
Post-translational modifications;
Dimerization;
Small molecule inhibitor
- From:
Cancer Research on Prevention and Treatment
2024;51(6):475-483
- CountryChina
- Language:Chinese
-
Abstract:
ERK1/2 is a key protein that mediates cell signal transduction, and it is involved in regulating biological processes such as chromatin remodeling, nuclear disintegration, proliferation, survival, metabolism, and cell migration and differentiation. Its overactivation is closely related to the occurrence and progression of cancer, and the mechanism is manifested as the overactivation of ERK1/2 by gene mutations of upstream pathway molecules or regulators and the reactivation of ERK1/2 after inhibition against the above targets. ERK1/2 is a potentially valuable target. In this review, the mechanism of post-translational modification and spatial regulation of ERK1/2 and the application status of corresponding small-molecule inhibitors were discussed. The current antitumor strategy of targeting and regulating ERK1/2 was summarized, and the possibility of exploring potential targets was elucidated, thus providing new insights into the developmental research of ERK1/2 as an ideal anticancer target.
